Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2026 06:41 ET | Source: Research and Markets

Cancer Cachexia Market Poised to Reach USD 3.90 Billion by 2033

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Cancer Cachexia Market Size, Share & Trends Analysis Report by Treatment (Appetite Stimulants, Corticosteroids), Type (Lung Cancer, Colorectal...
December 03, 2025 07:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader

Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.
November 27, 2025 08:17 ET | Source: Research and Markets

C-Met-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of c-Met-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 19, 2025 11:06 ET | Source: Research and Markets

Oncology Collaboration and Licensing Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 3,000+ Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the report...
November 10, 2025 07:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic...
November 04, 2025 10:00 ET | Source: PersonaDx

PersonaDx Co-Founder Dr. Sean Pitroda Awarded $1 Million Falk Medical Research Trust Grant

Chicago, IL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- PersonaDx, a precision diagnostic oncology company transforming how metastatic cancers are classified and treated, announced today that its co-founder...
October 24, 2025 11:45 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC
October 13, 2025 09:32 ET | Source: Research and Markets

AI in Oncology Market Industry Trends and Global Forecasts to 2035 | Artificial Intelligence in Oncology Market Set for $9.1B by 2035, Fueled by Early Detection and Precision Cancer Therapies

Dublin, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The "AI in Oncology Market Industry Trends and Global Forecasts to 2035, by Type of Cancer, Type of End-Users and Key Geographical Regions" report has been...
October 01, 2025 07:58 ET | Source: Research and Markets

Middle East AI in Oncology Market Size, Share & Trends Analysis Report 2025-2033 - Saudi Arabia's Cancer Cases Set to Increase 116.7% by 2040; AI Steps Up

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Middle East AI in Oncology Market Size, Share & Trends Analysis Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The...
September 25, 2025 00:08 ET | Source: Immuneering Corporation

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A